Checkmate: kidney injury associated with targeted cancer immunotherapy.
Level V
Where this comes from
- Record sourced from PubMed, PMID 27521108.
- Also identified by DOI 10.1016/j.kint.2016.05.024.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint inhibitors are a class of drugs that utilizes immunotherapy to target various cancers. Included are the anti-CTLA-4 and anti-PD-1 receptor antibodies. By reprogramming the immune system, these agents provide a therapy that destroys cancer cells. However, this approach runs the risk of allowing pathologic autoimmunity and organ injury to develop. Unsurprisingly, immune-related adverse effects are described including pneumonitis, colitis, and various endocrinopathies. Now added to this list is AKI, primarily due to ATIN.
Medical subject headings
- Immunotherapy
- Programmed Cell Death 1 Receptor